Congestive heart failure is an inexorable disease associated with unacceptably high morbidity and mortality. Preclinical results indicate that gene transfer using various proteins is a safe and effective approach for increasing function of the failing heart. In the current review, we provide a summary of cardiac gene transfer in general and summarize findings using adenylyl cyclase 6 as therapeutic gene in the failing heart. We also discuss the potential usefulness of a new treatment for congestive heart failure, paracrine-based gene transfer.
INTRODUCTION
Congestive heart failure (CHF) is a major cause of morbidity and mortality with increasing social and economic costs. 1 CHF is the only cardiovascular disease that is increasing in prevalence, and there are currently 6 million people in the United States and 423 million worldwide with CHF. Patients with CHF who have symptoms with mild activity or at rest (Class III and Class IV) have a poor long-term outcome, with up to 50% of patients dying within 4 years of symptom onset despite advanced pharmacological and device therapies. 2 Heart transplantation has an 80% 5-year survival rate, but fewer than 2500 cardiac transplants are performed in the United State each year. Because the prevalence of CHF is increasing and outlook remains dismal, new therapeutic approaches for CHF, including gene transfer, are warranted.
Several factors have impeded the advancement of clinical gene transfer for the treatment of CHF. These impediments include selection of (a) an effective gene; (b) suitable vectors and promoters with high efficiency and long-term expression with minimal toxicity and immunogenicity; and (c) delivery methods that are easy to deploy and result in safe and effective expression in the heart with minimal adverse effects. It is encouraging that virus-mediated gene transfer of a number of genes appears to increase cardiac function in animal models of heart failure. [3] [4] [5] [6] [7] At present, clinical trials using virusmediated gene transfer of sarcoendoplasmic reticulum Ca 2+ ATPase 2a (SERCA2a) and adenylyl cyclase 6 (AC6) for CHF are in progress. Other potential gene transfer proteins, with preclinical data indicating efficacy in CHF treatment, include bARKct, an inhibitor of G-proteincoupled receptor kinases, and S100A1. 8 We now will review cardiac gene transfer briefly, discuss cardiac AC6 gene transfer for CHF, and introduce an alternative approach, paracrine-based gene transfer. The exciting findings from preclinical studies using other potentially therapeutic proteins to increase function of the failing heart are reviewed elsewhere in this issue of Gene Therapy.
CARDIAC GENE TRANSFER
For CHF treatment, the goal has been to deliver vectors encoding therapeutic genes safely and effectively to the heart. Although we will discuss separately the selection of therapeutic genes, vectors, promoters and delivery methods, these components ultimately must be considered collectively to select the most effective gene transfer approach.
Selection of therapeutic genes for CHF Cyclic AMP (cAMP; 3¢-5¢-cyclic adenosine monophosphate) and Ca 2+ handling profoundly influence left ventricular (LV) contractile function and relaxation. It is not surprising that a majority of promising therapeutic genes for CHF target defective cAMP or Ca 2+ handling in cardiac myocytes. Additionally, decreasing myocardial ischemia by increasing myocardial blood flow is an attractive approach for myocardial infarction-induced CHF and also for CHF in general. Although myocardial ischemia most commonly is treated by coronary artery bypass graft surgery and percutaneous coronary interventions, there may be a role for angiogenic gene transfer. [9] [10] [11] This strategy has been reviewed elsewhere 12, 13 and will not be discussed further here. Manipulation of RNA stability and protein synthesis by small RNAs (for example, microRNA) may provide new options for CHF gene transfer. However, concerns about specificity must first be resolved. 14 b-Adrenergic receptor signaling pathway. CHF is generally associated with impaired b-adrenergic receptor (bAR) responsiveness, and elevated circulating catecholamine levels. Changes in LV contractility are associated with bAR downregulation and desensitization, bAR uncoupling, reduced expression or function of adenylyl cyclase (AC), and impaired cAMP generating capacity. 15 Pharmacological attempts to increase LV function in clinical CHF by increasing cAMP signaling have failed. In animal studies, chronic infusion of isoproterenol (a bAR agonist) and cardiac-directed expression of b 1 AR, Gas and cAMP-dependent protein kinase A all have resulted in cardiomyopathy. Dobutamine (a bAR agonist) and milrinone (a phosphodiesterase inhibitor that increases intracellular cAMP levels) increase cardiac contractile function in clinical CHF, but patients do not get a survival advantage, and milrinone increases mortality. 16 These deleterious effects are presumed to result from sustained increases in cAMP production.
Indeed, cardiac-directed expression of constitutively active human b 1 AR is associated with cardiomyopathy. 17, 18 Deletion of G-protein-coupled receptor kinase 2 (a kinase that attenuates bAR signaling) restores bAR responsiveness in the failing heart and increases cardiac function and survival. 19 Inhibition of G-protein-coupled receptor kinase 2 by bARKct, a 195 amino-acid C-terminal fragment of G-protein-coupled receptor kinase 2, also increases contractile function in several animal models of CHF and in failing human cardiac myocytes. 8 These effects are associated with normalization of bAR density and bAR signaling. Importantly, bARKct and bAR blockade appear to act synergistically to increase bAR signaling to normal levels, 20 although bARKct also may increase cardiac function by regulating Gbg and apoptosis signaling. 21, 22 It is surprising that expression of AC6, the enzyme catalyzing cAMP formation, shows beneficial effects on the failing heart. These beneficial effects reflect unique feature of AC6, not shared by other elements of the bAR-Gs-AC pathway. For example, AC6 expression does not affect basal cAMP production in the normal heart, and may increase cardiac function through cAMP-independent mechanisms. These features of AC6 will be discussed in more detail below.
Ca 2+ handling. Ca 2+ directly regulates cardiac contraction and relaxation. CHF is associated with defective sarcoplasmic reticulum (SR) Ca 2+ uptake and Ca 2+ release. Ca 2+ sensitivity of the contractile apparatus is also impaired in CHF. It is therefore logical to consider strategies to improve cardiac function by correcting defective Ca 2+ handling using gene transfer.
Preclinical studies in animal models of CHF have identified SERCA2a as a promising candidate for gene transfer. 23, 24 A study of transgenic rats with cardiac-directed SERCA2a expression showed provocation of cardiac dysrhythmias, 25 but similar problems were not apparent in subsequent studies using SERCA2a gene transfer. 26, 27 Intracoronary delivery of adeno-associated virus (AAV) encoding SERCA2a appears to be safe in a trial of 39 subjects with CHF. 27 These results indicate the potential safety of intracoronary delivery of AAV vectors in patients with CHF. S100A1 belongs to the family of S100 EF-hand Ca 2+ -binding proteins. Expression of S100A1 increases SERCA2a Ca 2+ uptake activity, and also stabilizes the release of Ca 2+ channel ryanodine receptor in the failing heart. 28 Interestingly, S100A1 expression and bAR blockade act synergistically to improve LV function.
Other Ca 2+ handling regulators (for example, protein phosphatase inhibitor 1, sorcin and parvalbumin) also show favorable effects on LV function in animal models of cardiomyopathy after virus-mediated gene transfer. Further studies are warranted to establish their usefulness in clinical CHF.
Selection of vectors
The ideal vectors for cardiac gene transfer should exhibit (1) high level expression; (2) limited off-target expression; (3) long-term expression; and (4) minimal toxicity and immunogenicity. In general, virus vectors provide superior cardiac transgene expression to non-virus vectors. Regulated expression is also desirable, but the limited capacity of vectors and large size of transgenes currently used in intracoronary delivery generally preclude its use.
The commonly used virus vectors for cardiac gene transfer are adenovirus, AAV and lentivirus. More detailed information regarding commonly used vectors have been reviewed elsewhere, 29 and only brief mention will be made here. AAV has less immunogenicity and may provide long-term expression. However, its small packaging capacity limits the size of gene expression cassette (including promoter, regulatory elements and transgene) to less than 5 kb. Lentivirus has larger packaging capacity and also low immunogenicity, but cannot easily move across the endothelial cell, thus lentivirus is unsuited for intracoronary delivery. 30 Selection of delivery methods Detectable gene transfer to the heart has been achieved by several delivery methods. Direct intramyocardial injection provides transgene expression along the injected area. Intracoronary delivery of adenovirus is not typically associated with myocardial inflammation, except at extremely high doses, 31 but direct myocardial injection can cause inflammation. 32, 33 Intracoronary delivery of AAV2 is less efficient than adenovirus, 34 providing a rationale for selection of adenovirus in the AC6 clinical trial. Although intravenous delivery of newer AAV vectors (AAV6, AAV8 and AAV9) appears to provide substantial cardiac gene transfer, expression in the liver and other organs is also robust. 35 The use of the term 'cardiotropic' for these vectors is misleading because it suggests cardiac specificity, which clearly does not occur. A potential shortcoming for intravenous delivery of AAV vectors is that the high dose of AAV required to ensure adequate cardiac gene transfer, which limits its clinical application.
Indirect intracoronary delivery is required in rodents, because the small caliber of the coronary arteries in mice and rats precluded direct intraluminal insertion. In this procedure, the ascending aorta and pulmonary artery are clamped, and virus vectors injected into the LV chamber are forced into the coronary arteries. In conjunction with hypothermia, indirect intracoronary delivery enables prolonged dwell time without ischemic injury to the heart and brain. These methods have been invaluable in cardiac gene transfer in rodents, and provide superior levels of cardiac transgene expression compared with intravenous delivery, even with AAV5, AAV6 and AAV9 (unpublished data).
Pharmacological agents that promote transcytosis after vascular delivery of vector can increase gene transfer efficiency. Such pharmacological agents, including histamine, nitroprusside, serotonin, acetylcholine, sildenafil, vascular endothelial growth factor and substance P, facilitate transvascular movement of virus vectors across the endothelial border into the cardiac interstitium. Finally, a percutaneous closed-loop recirculation system has been used to increase AAVmediated cardiac gene transfer in sheep. 7 Selection of delivery method should be considered in the context of several factors, including vector type, species and organ targeted, to obtain optimal results. Because of the safety concerns, invasive methods requiring thoracotomy, cross-clamping of the aorta or cardiopulmonary bypass are not applicable in clinical settings. Refinements in methods of delivery have improved transgene expression. The vector delivery method easiest to apply, safest and most effective will ultimately be the one adopted for clinical applications.
AC6: A PROMISING CANDIDATE FOR GENE TRANSFER
AC is the enzyme that converts ATP to cAMP. In cardiac myocytes, AC6 and AC5 are the two dominant AC isoforms. AC5 and AC6 have 65% amino-acid homology, and each contribute equally to cAMP generation in cardiac myocytes and LV membranes. 36, 37 Deletion of AC5 mildly increases SR Ca 2+ handling and LV function. 36 In contrast, deletion of AC6 is associated with marked impairment of Ca 2+ signaling and LV function. 37 These observations suggest that modulating cardiac AC6 content would have favorable effects on the failing heart (Table 1) .
AC6 Increases LV responsiveness to bAR stimulation
As previously alluded to, cAMP signaling is of pivotal importance in LV contraction and relaxation. AC6 protein content sets a limit on bAR-dependent cAMP generation in cardiac myocytes. 38 Transgenic mice with cardiac-directed expression of AC6 show increased cAMP generating capacity in cardiac myocytes after bAR stimulation, but no change in cardiac bAR density or protein contents of Gas and Gai2. 39, 40 Associated with increased cAMP generating capacity is increased LV contractile function and relaxation in response to bAR stimulation. Conversely, AC6 deletion is associated with decreased LV function and bAR responsiveness. 37 Moreover, AC6 gene transfer via intracoronary delivery increases LV function in response to bAR stimulation in mice and pigs. 41, 42 AC6 expression has no effect on basal LV function or basal cAMP production in LV membranes or cardiac myocytes. 41 When expressed at high levels (10-to 20-fold increase in AC6 protein) for 420 months, no abnormalities are seen in LV size or basal function, and such mice have normal longevity. 40 Unaltered basal cAMP production is unique to the AC6 transgenic mouse: it is not seen when other elements of the bAR signaling pathway are expressed in the hearts of transgenic lines (b1AR, Gsa, protein kinase A). This unique feature of cardiac AC6 expression may in part explain why cardiac-directed AC6 expression is beneficial rather than deleterious.
AC6 improves defective Ca 2+ handling in the failing heart Mimicking important aspects of clinical CHF, Gaq cardiomyopathy is associated with impaired cAMP production, defective Ca 2+ handling, LV hypertrophy, dilation, and abnormal LV systolic and diastolic function. 43 Expression of AC6 in this cardiomyopathic background increases LV contractile function and relaxation, attenuates LV hypertrophy and dilation, and increases survival. [44] [45] [46] AC6 expression is not associated with increases in heart rate or arrythmias. 47 Correction of defects in bAR-stimulated cAMP production and SR Ca 2+ uptake by AC6 expression are of mechanistic importance for these functional improvements. 48 In addition, patch clamping shows that AC6 expression corrects prolonged action potential associated with Gaq cardiomyopathy, suggesting a possible beneficial role of AC6 in attenuating ventricular arrythmias. 49 AC6 expression also increases survival by two fold after acute myocardial infarction, although it has no effect on infarct size. 50 This favorable effect of AC6 on survival may be resulted from increased LV function and reduced LV dilation. Increased LV function is associated with increased phospholamban (PLB) phosphorylation, SR Ca 2+ uptake and SERCA2a affinity to Ca 2+ , in addition to reduced AV block. AC6 expression also increases engraftment of inducible pluripotent stem cells in the infarcted area, suggesting a novel function of AC6 in the setting of myocardial ischemia. 51 In mice with severe CHF induced by myocardial infarction, activation of cardiac AC6 expression increases LV contractility and reduces LV dilation, as shown by increases in LV ejection fraction, pressure development (LV +dP/dt), cardiac output and slope of the endsystolic pressure-volume relationship. Diastolic function is also improved by the activation of cardiac AC6 expression. Similarly, AC6 gene transfer in pacing-induced CHF in pigs shows favorable effects on LV function and reduces LV chamber dilation, thereby reducing LV end-systolic wall stress. 42 Associated with these favorable effects are increases in bAR-stimulated cAMP production, protein kinase A activity and cardiac troponin I phosphorylation at Ser23/24. 3 No change is found in protein contents of other signaling elements important for LV function. As cardiac troponin I phosphorylation at Ser23/24 is critical for increase of off-rate for Ca 2+ exchange with cTnC and also for improvement of LV function in CHF, 52, 53 these results suggest that increased cardiac troponin I phosphorylation is important for AC6 function in the failing heart.
A recent publication indicated that constitutive cardiac expression of AC6 has a deleterious effect on LV function in mice 4 weeks after proximal aortic constriction, 54 but a subsequent paper showed beneficial effects in the same model using regulated AC6 expression. 55 
AC6 increases function in the aged heart
Cell senescence is associated with reduced LV function and impaired bAR responsiveness in aged myocardium. 1,2 LV contractile reserve at age 80 years is less than one-half of that at age 20 years. This agerelated reduction of cardiac function affects the severity and prognosis of CHF in the elderly. 2 Epidemiological studies have found that CHF is a common disease of the elderly. 1,2 The incidence of CHF in the United States is 1% in people aged 65 years and older and increases to over 30% at age 80 years. 2 In the aging heart, reduced LV function and bAR responsiveness occur in the presence of increased plasma catecholamine levels, 56 indicating an abnormality in AC signaling. Reduced cardiac AC6 expression and impaired LV cAMP generation capacity is associated with advanced age. The hypothesis that increased AC6 protein content in the aged myocardium increases LV function was tested using a transgenic mouse line with regulated AC6 expression. 57 Activation of cardiac AC6 expression in aged mice (aged 20 months) improves LV +dP/dt, stroke work, end-systolic pressure-volume relationship and ÀdP/dt. 57 These changes in contractile function and relaxation are associated with increased SR Ca 2+ uptake and SERCA2a affinity for Ca 2+ . There is no evidence of LV hypertrophy or fibrosis after activation of AC6 expression in the aged myocardium. Activation of AC6 expression is also associated with increased cAMP generating capacity, cAMP-dependent protein kinase activity, cardiac troponin I phosphorylation and PLB phosphorylation. There are no changes in fetal gene expression, SERCA2a protein content, calsequestrin protein content and Na + -Ca 2+ exchanger protein content. Interestingly, activation of AC6 expression has no effect on LV contractile function and relaxation in young mice (aged 7 months).
AC6 and cAMP-independent effects
In addition to cAMP-dependent events, AC6 expression affects cell signaling through mechanism independent of cAMP generation (Figure 1 ). For example, AC6 gene transfer increases protein content of ATF3 (activating transcription factor 3), which in turn suppresses gene transcription of atrial natriuretic factor (ANF) and PLB. These effects of AC6 occur in the absence of catecholamines and in the presence of specific protein kinase A inhibitors, suggesting that they are independent of cAMP signaling. [58] [59] [60] Decreased PLB content would be predicted to increase SR Ca 2+ uptake by SERCA2a and have a favorable effect on cardiac myocyte contractile function and relaxation. AC6 also directly binds to PHLPP2 (pleckstrin homology domain leucine-rich protein phosphatase 2) and prevents PHLPP2 inhibition on Akt activity in cardiac myocytes. 59 Activated Akt can phosphorylate PLB at Ser16 site, although PLB is not a good substrate for Akt. 60 Like native form of AC6, an AC6 mutant (AC6mut) with marked impairment in cAMP generation, influences intracellular signaling events. AC6mut also activates Akt, increases ATF3 expression and reduces PLB expression. These data confirm that many of the effects of AC6 on cell signaling do not require increased cAMP generation. Additional studies are warranted to investigate the relative importance of cAMP-dependent versus cAMP-independent cell signaling in regulating cardiac myocyte and LV function.
In summary, these studies demonstrate that AC6 expression has protean cardiac effects, both cAMP-dependent and cAMP-independent, and safely increases function of the failing heart (Table 1) . Based on these results, a clinical trial of cardiac AC6 gene transfer in CHF patients is in progress (ClinicalTrials.gov, NCT00787059). This randomized, double-blinded, placebo-controlled trial will evaluate the safety and clinical effectiveness of ascending doses of human adenovirus-5 (E1/E3-deleted, replication incompetent) encoding human AC6 (Ad5.hAC6) by intracoronary delivery. Figure 1 Hypothetical model of cAMP-independent effects of AC6 gene transfer. Cardiac AC6 expression has beneficial cardiac effects, through both (a) cAMP-dependent and (b) cAMP-independent events. The hypothetical mechanistic model summarizes data from experiments using adenovirusmediated gene transfer of AC6 in cultured cardiac myocytes. Transgene AC6, widely distributed in the cytoplasm owing to gene transfer, has access to previously inaccessible intracellular proteins and cytoplasmic compartments. For example, AC6 is associated with the nuclear envelope and increased nuclear ATF3 expression is observed, which reduces PLB expression. 58 Association of transgene AC6 with PHLPP2 (an Akt phosphatase) reduces its phosphatase activity, promoting Akt activation and subsequent PLB phosphorylation. 59, 60 The effects of transgene AC6 on PLB, which promote calcium handling and contractile function, are cAMP independent. a, Gas subunit; bg, Gbg subunits; Akt-P, Akt phosphorylation; ATF3, activating transcription factor 3; C1, AC6 catalytic domain 1; C2, AC6 catalytic domain 2; LV, left ventricular; M1, AC6 transmembrane domain 1; M2, AC6 transmembrane domain 2; PHLPP2, pleckstrin homology domain leucinerich repeat protein phosphatase 2; PKA, cAMP-dependent protein kinase A; PLB, phospholamban; PLB-P, phospholamban phosphorylation.
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PARACRINE-BASED GENE TRANSFER
Gene transfer for the treatment of cardiovascular diseases is conceptually attractive, but difficulty in obtaining a high-yield transgene expression in the heart, in a manner that can be easily and safely applied, has been a chief impediment to progress. Current potential methods of gene transfer for clinical heart disease include intramuscular injection into heart muscle, intracoronary delivery or percutaneous recirculation-methods that typically provide limited expression or are cumbersome to apply. Consequently, clinical cardiac gene therapy trials have been somewhat disappointing likely because of failure to obtain adequate gene expression in the heart to attain a beneficial effect.
To circumvent this problem, we have considered the usefulness of a vector encoding a paracrine-type transgene, which affects cardiac function after being released to the circulation from distant sites. For example, systemic delivery of a long-term expression vector encoding a paracrine gene would enable sustained release of the transgene to serum, where it could exert beneficial effects on the heart 'from a distance' . Such an approach would limit the number of candidate genes-insulin-like growth factor-I (IGF-I), growth hormone, B-type natriuretic peptide, urocortin-2 (to name a few)-but may enhance the prospects of successful clinical gene therapy for CHF. An additional advantage of this approach is that it would enable CHF patients to be treated by a simple intravenous injection during an office visit, circumventing the need for more expensive and potentially hazardous invasive procedures such as cardiac catheterization and intracoronary vector delivery.
A seminal paper in clinical gene therapy recently reports that intravenous delivery of an AAV vector increases serum levels of transgene in a sustained manner safely and effectively. 61 This is demonstrated in human subjects with hemophilia B using AAV8 encoding human Factor IX, which is deficient in such patients. Although this study is by necessity limited to a few subjects (n¼6), sustained increases in serum levels of Factor IX are documented, and transfusion requirements are reduced, demonstrating a clinical benefit. This paper documents proof of concept for the paracrine approach, and could be tailored easily for application to clinical CHF.
In considering such an approach, the use of a long-term expression vector such as AAV necessitates regulation of transgene expression. Integrating a regulation system (for example, tetracycline-regulated or rapamycin-regulated system) 62, 63 into the AAV vector would enable turning transgene expression off in the event of untoward effects. For example, if such effects occur, the subject would simply stop taking the activating compound (tetracycline or rapamycin analog). Regulated expression would also enable intermittent rather than constant transgene expression, allowing the physician and patient to tailor therapy by altering the oral dose of activating agents. Doses as low as 10-20 mg doxycycline on alternate days could be adequate to activate the more recent tetracycline-regulation systems. 64 To test the feasibility of paracrine-based gene transfer in the failing heart, we injected an AAV5 vector encoding IGF-I under tetracyclineregulated expression (AAV5.IGFI-tet) into skeletal muscle of rats with myocardial infarction-induced severe CHF. 63 IGF-I is a peptide with protean favorable cardiovascular effects (inotropic, angiogenic, antiapoptotic). Five weeks after gene transfer, 50% of the rats were randomized to receive doxycycline in their water supply (to activate IGF-I expression; IGF-On); the remaining rats did not receive doxycycline and served as controls (IGF-Off). IGF-On rats showed increased LV ejection fraction (P¼0.02) and reduced LV end-systolic diameter (P¼0.03). Furthermore, LV contractile function, assessed by the rate of pressure development (LV +dP/dt) during dobutamine infusion, is increased after initiation of IGF-I expression (P¼0.001). In addition, favorable changes in cardiac output (P¼0.007) and stroke work (P¼0.003) are observed. Serum IGF-I is increased 5 weeks after transgene activation (IGF-Off: 164 ± 24 ng ml À1 ; IGF-On: 218 ± 11 ng ml À1 ; P¼0.008; n¼9 each group). These data indicate that skeletal muscle injection of AAV5.IGFI-tet enables tetracyclineactivated expression, increases serum IGF-I levels and improves function of the failing heart. 63 Translation of these studies to clinical trials will require selection of the optimal AAV vector (likely to be AAV8 or AAV9 rather than AAV5), and intravenous rather than intramuscular delivery. For example, clinical trials in hemophilia that employed intramuscular delivery of AAV vectors are associated with immune responses that abrogated therapeutic Factor IX levels, 65, 66 a problem that is subsequently circumvented by intravenous delivery. 61 Paracrine-based gene transfer may be suitable for any circulating peptide with beneficial cardiovascular effects. For example, in addition to IGF-I and growth hormone, B-type natriuretic peptide is another biologically effective peptide used for the treatment of clinical CHF that could be delivered in a similar manner. Moreover, prostacyclin analogs can be effective in treating pulmonary hypertension. Current agents (epoprostenol and trepostinil) require constant systemic injection, and the treatment itself is associated with high morbidity. 67 A regulated expression vector encoding prostacyclin synthase is a plausible paracrine-type gene therapy of pulmonary hypertension.
CONCLUSION
Gene transfer for the treatment of CHF is justified because there is an unmet medical need for treating CHF, and gene transfer, based on preclinical studies, has the potential to meet that need. Preclinical studies have documented the therapeutic potential in CHF of many genes, two of which have advanced to clinical trials: SERCA2a and AC6. However, the major impediment to progress has been the difficulty in obtaining a high-yield transgene expression in the heart. One approach that could potentially circumvent this problem is paracrinebased gene transfer, in which systemic injection of a long-term regulated expression vector encoding a paracrine gene with favorable cardiovascular effects. Whether this approach can overcome numerous obstacles and improve prospects for successful cardiovascular gene therapy is unknown, but preclinical studies are promising. A final note: cell-based therapy has not yet been demonstrated to be effective in double-blinded, placebo-controlled, randomized clinical trials of CHF. Gene transfer is simpler, easier to regulate, and, based upon preclinical studies just as promising as cell therapy. It will be interesting to see which of these approaches is more useful in the treatment of clinical CHF.
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